β-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells

Molecular Medicine Reports

Volumn 9, Issue 3, 2014, Pages 973-978

  Wang, Shao Hua ^a   Li, Ning ^a   Wei, Yao ^a   Li, Qiu Rong ^a   Yu, Ze Ping ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

catenin; Acetylation; Breast cancer; P300; WNT

Indexed keywords

ACETYLATION; AXIN PROTEIN; BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HISTONE DEACETYLASES; HUMANS; MCF-7 CELLS; MUTATION; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; T CELL TRANSCRIPTION FACTOR 1; UP-REGULATION; WNT SIGNALING PATHWAY; WNT3A PROTEIN;

EID: 84893828036     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1889     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
3. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480, 2006.
4. van Amerongen R, Mikels A and Nusse R: Alternative wnt signaling is initiated by distinct receptors. Sci Signal 1: re9, 2008.
5. MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 17: 9-26, 2009.
6. Howe LR and Brown AM: Wnt signaling and breast cancer. Cancer Biol Ther 3: 36-41, 2004.
7. van de Wetering M, Barker N, Harkes IC, et al: Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res 61: 278-284, 2001.
8. Bafico A, Liu G, Goldin L, Harris V and Aaronson SA: An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 6: 497-506, 2004.
9. Schlange T, Matsuda Y, Lienhard S, Huber A and Hynes NE: Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res 9: R63, 2007.
10. Matsuda Y, Schlange T, Oakeley EJ, Boulay A and Hynes NE: WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth. Breast Cancer Res 11: R32, 2009.
11. Nelson WJ and Nusse R: Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303: 1483-1487, 2004.
12. Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y and Cao X: The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol 11: 487-494, 2010.
13. Liu C, Li Y, Semenov M, et al: Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108: 837-847, 2002.
14. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S and Kikuchi A: Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 17: 1371-1384, 1998.
15. Kitagawa M, Hatakeyama S, Shirane M, et al: An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin. EMBO J 18: 2401-2410, 1999.
16. Yost C, Torres M, Miller JR, Huang E, Kimelman D and Moon RT: The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase. Genes Dev 10: 1443-1454, 1996
17. Liu C, Kato Y, Zhang Z, Do VM, Yankner BA and He X: beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci USA 96: 6273-6278, 1999.
18. Wolf D, Rodova M, Miska EA, Calvet JP and Kouzarides T: Acetylation of beta-catenin by gapdh (CBP). J Biol Chem 277: 25562-25567, 2002.
19. Levy L, Wei Y, Labalette C, Wu Y, Renard CA, Buendia MA and Neuveut C: Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol 24: 3404-3414, 2004.
20. Zhu J, Coyne CB and Sarkar SN: PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and β-catenin. EMBO J 30: 4838-4849, 2011.
21. Jho EH, Zhang T, Domon C, Joo CK, Freund JN and Costantini F: Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22: 1172-1183, 2002.
22. Roose J, Huls G, van Beest M, et al: Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 285: 1923-1926, 1999.
23. Li Y, Zhang X, Polakiewicz RD, Yao TP and Comb MJ: HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem 283: 12686-12690, 2008.
24. Takahashi-Yanaga F and Sasaguri T: The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci 104: 293-302, 2007.
25. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790, 1997.
26. Fraga MF, Ballestar E, Villar-Garea A, et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400, 2005.
27. Lin YY, Kiihl S, Suhail Y, et al: Functional dissection of lysine deacetylases reveals that HDAC1 and p300 regulate AMPK. Nature 482: 251-255, 2012.
28. von Kries JP, Winbeck G, Asbrand C, et al: Hot spots in beta-catenin for interactions with LEF-1, conductin and APC. Nat Struct Biol 7: 800-807, 2000.